Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial

依维莫司 伦瓦提尼 医学 肾细胞癌 内科学 肿瘤科 人口 索拉非尼 泌尿科 环境卫生 肝细胞癌
作者
Robert John Motzer,Thomas E. Hutson,Hilary Glen,Marc Dror Michaelson,Ana M. Molina,Timothy Eisen,Jacek Jassem,Jakub Żołnierek,Pablo Maroto,Begoña Mellado,Bohuslav Melichar,Jiří Tomášek,Alton B. Kremer,Hanjoo Kim,Karen Wood,Corina E. Dutcus,James Larkin
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:16 (15): 1473-1482 被引量:1022
标识
DOI:10.1016/s1470-2045(15)00290-9
摘要

Background Currently, metastatic renal cell carcinoma is treated with sequential single agents targeting VEGF or mTOR. Here, we aimed to assess lenvatinib, everolimus, or their combination as second-line treatment in patients with metastatic renal cell carcinoma. Methods We did a randomised, phase 2, open-label, multicentre trial at 37 centres in five countries and enrolled patients with advanced or metastatic, clear-cell, renal cell carcinoma. We included patients who had received treatment with a VEGF-targeted therapy and progressed on or within 9 months of stopping that agent. Patients were randomised via an interactive voice response system in a 1:1:1 ratio to either lenvatinib (24 mg/day), everolimus (10 mg/day), or lenvatinib plus everolimus (18 mg/day and 5 mg/day, respectively) administered orally in continuous 28-day cycles until disease progression or unacceptable toxic effects. The randomisation procedure dynamically minimised imbalances between treatment groups for the stratification factors haemoglobin and corrected serum calcium. The primary objective was progression-free survival in the intention-to-treat population. This study is closed to enrolment but patients' treatment and follow-up is ongoing. This study is registered with ClinicalTrials.gov, number NCT01136733. Findings Between March 16, 2012, and June 19, 2013, 153 patients were randomly allocated to receive either the combination of lenvatinib plus everolimus (n=51), single-agent lenvatinib (n=52), or single-agent everolimus (n=50). Lenvatinib plus everolimus significantly prolonged progression-free survival compared with everolimus alone (median 14·6 months [95% CI 5·9–20·1] vs 5·5 months [3·5–7·1]; hazard ratio [HR] 0·40, 95% CI 0·24–0·68; p=0·0005), but not compared with lenvatinib alone (7·4 months [95% CI 5·6–10·2]; HR 0·66, 95% CI 0·39–1·10; p=0·12). Single-agent lenvatinib significantly prolonged progression-free survival compared with everolimus alone (HR 0·61, 95% CI 0·38–0·98; p=0·048). Grade 3 and 4 events occurred in fewer patients allocated single-agent everolimus (25 [50%]) compared with those assigned lenvatinib alone (41 [79%]) or lenvatinib plus everolimus (36 [71%]). The most common grade 3 or 4 treatment-emergent adverse event in patients allocated lenvatinib plus everolimus was diarrhoea (ten [20%]), in those assigned single-agent lenvatinib it was proteinuria (ten [19%]), and in those assigned single-agent everolimus it was anaemia (six [12%]). Two deaths were deemed related to study drug, one cerebral haemorrhage in the lenvatinib plus everolimus group and one myocardial infarction with single-agent lenvatinib. Interpretation Lenvatinib plus everolimus and lenvatinib alone resulted in a progression-free survival benefit for patients with metastatic renal cell carcinoma who have progressed after one previous VEGF-targeted therapy. Further study of lenvatinib is warranted in patients with metastatic renal cell carcinoma. Funding Eisai Inc.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
隐形曼青的应助被研小窝采纳,获得10
刚刚
xiaot发布了新的文献求助10
1秒前
1秒前
共享精神的应助被小小小先生采纳,获得10
1秒前
领导范儿的应助被Clarissa采纳,获得10
1秒前
呵呵壕完成签到,获得积分10
1秒前
打打的应助被搞怪的又蓝采纳,获得10
1秒前
科研通AI6.2的应助被Swu采纳,获得10
2秒前
2秒前
何鸿成发布了新的文献求助10
2秒前
2秒前
2秒前
3秒前
3秒前
安澜完成签到,获得积分10
3秒前
3秒前
hyn发布了新的文献求助10
3秒前
比比拉布完成签到 ,获得积分10
3秒前
3秒前
wch666发布了新的文献求助10
3秒前
3秒前
任性乞完成签到 ,获得积分10
4秒前
5秒前
5秒前
5秒前
杨淇升发布了新的文献求助10
5秒前
天熙完成签到,获得积分10
5秒前
04d的应助被dxq采纳,获得20
5秒前
5秒前
迷你的冰巧完成签到,获得积分10
5秒前
6秒前
6秒前
6秒前
Lidandan完成签到,获得积分10
6秒前
6秒前
6秒前
6秒前
6秒前
6秒前
呵呵发布了新的文献求助10
6秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8162918
求助须知:如何正确求助?哪些是违规求助? 9557210
关于积分的说明 21738626
捐赠科研通 7753447
什么是DOI,文献DOI怎么找? 3427983
关于科研通互助平台的介绍 2552768
邀请新用户注册赠送积分活动 2472619